Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2019 | Inhibition of C3 with APL-2 in autoimmune hemolytic anemia to reduce hemolysis

Bruno Fattizzo • 2 Apr 2019
BSH 2019
Anemias Pegcetacoplan

Bruno Fattizzo, MD, of the University of Milan, Milan, Italy, speaks at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK. He discusses his research on the effects of pegcetacoplan, a C3 inhibitor, on hemolysis in autoimmune hemolytic anemia (AIHA).

More from Bruno Fattizzo

1:13
Pegcetacoplan: mechanism of action within the complement system
Bruno Fattizzo • 2 Apr 2019

Related Videos

3:45
A 2-year analysis of the EBMT-SAAWP RACE trial: eltrombopag in aplastic anemia
Antonio Risitano • 16 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:31
Mitapivat improves work/school attendance in patients with pyruvate kinase deficiency
Hanny Al-Samkari • 9 Dec 2023
2:13
SATISFY: mitapivat in patients with erythrocyte membranopathies
Kevin Kuo • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals